Given the significant between‐study heterogeneity for first‐generation tracers, the results of the present study support the shift towards the application of second‐generation tau PET tracers in the exploration of differential diagnostic biomarkers for PSP and CBD. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.